



Improvement of Clinical Outcomes of Total Aortic Arch Replacement and Frozen Elephant Trunk Surgery With Aortic Balloon Occlusion

Luchen Wang¹, Zeyi Cheng², Yunfeng Li^{1,3}, Junpeng Li⁴, Hongwei Guo¹, Shenghua Liang¹ and Xiaogang Sun^{1*}

¹ Aortic and Vascular Surgery Center, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, ² Department of Cardiovascular Surgery, West China Hospital, Sichuan University, Chengdu, China, ³ Qilu Hospital, Shandong University, Jinan, China, ⁴ Huamei Hospital, University of Chinese Academy of Sciences, Ningbo, China

OPEN ACCESS

Edited by:

Antonio Miceli, Istituto Clinico Sant'Ambrogio, Italy

Reviewed by:

Giovanni Concistrè, Gabriele Monasterio Tuscany Foundation (CNR), Italy Francesco Pollari, Nürnberg Hospital, Germany Antonio Lio, San Camillo-Forlanini Hospital, Italy

> *Correspondence: Xiaogang Sun xiaogangsunl@163.com

Specialty section:

This article was submitted to Heart Surgery, a section of the journal Frontiers in Cardiovascular Medicine

> **Received:** 20 April 2021 **Accepted:** 21 June 2021 **Published:** 26 July 2021

Citation:

Wang L, Cheng Z, Li Y, Li J, Guo H, Liang S and Sun X (2021) Improvement of Clinical Outcomes of Total Aortic Arch Replacement and Frozen Elephant Trunk Surgery With Aortic Balloon Occlusion. Front. Cardiovasc. Med. 8:691615. doi: 10.3389/fcvm.2021.691615 **Background:** Total aortic arch replacement (TAR) with frozen elephant trunk (FET) surgery provides improved long-term results, but the surgery itself is associated with higher risks compared with isolated proximal reconstructions. We applied an aortic balloon occlusion (ABO) technique to reduce the circulatory arrest (CA) time and improve other clinical outcomes.

Methods: All patients who underwent TAR with FET surgery (130 with ABO technique, 230 with the conventional approach) in Fuwai Hospital from August 2017 to February 2019 were reviewed in this retrospective observational cohort study. Intra- and early-postoperative results and clinical characteristics were analyzed.

Results: After 1:1 propensity score matching (130 cases in each group), the 30-day mortality of the ABO group and the conventional group were 4.6% and 10.8% (p = 0.063), respectively. Although the reduction in complications was not statistically significant, the complication rate in the ABO group was relatively low, having fewer cases of postoperative renal (23.1 vs. 38.5%, p = 0.007) and hepatic (12.3 vs. 30.0%, p < 0.001) injury, lower postoperative wake-up time (15.2 ± 23.6 h vs. 20.1 ± 26.5 h, respectively, p < 0.001), reduced chest tube output (176.03 ± 143.73 ml vs. 213.29 ± 130.12 ml, respectively, p = 0.003), lower red blood cell transfusion volume (4.98 ± 6.53 u vs. 7.28 ± 10.41 u, respectively, p = 0.008), and no fatal events.

Conclusions: The ABO technique is a simple method that can reduce the CA time and improve the recovery stage following TAR with FET surgery. The technique represents a practical strategy to treat patients with high operative risks due to its lower complication rate compared with the conventional approach.

Keywords: aortic dissection, total aortic arch replacement, frozen elephant trunk, hypothermic circulatory arrest, aortic balloon occlusion technique

1

Total aortic arch replacement (TAR) with frozen elephant trunk (FET) surgery is considered the most reliable method in treating type A aortic dissection (AD) in our hospital (1–3). Currently, we routinely perform TAR with FET with a lower average circulatory arrest (CA) time (17 min) with a target temperature of 26° C in non-complicated cases; this has improved postoperative results compared with the past decades. This new technique used in TAR with FET surgery can reduce the lower body CA time to 5 min on average (4). The target lowest temperature for CA has now been raised to 28° C. This study was aimed to investigate the merits of our new technique by comparing the clinical endpoints according to the International Aortic Arch Surgery Study Group (IAASSG) (5). The laboratory test results were examined to further discuss the advantages of this new technique.

METHODS

Study Design and Patient Population

The study was approved by the institutional ethics committee of Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences, and Peking Union Medical College (Approval No. 2018-1069), and individual consent for this retrospective analysis was waived. The study was conducted in accordance with the Declaration of Helsinki (as revised in 2013). All data sets were represented by routine parameters from our institution that did not constitute an additional burden to the patients. The study included consecutive patients who underwent TAR with FET surgery in Fuwai Hospital from August 2017 to February 2019. A total of 130 patients underwent TAR with FET surgery via the balloon occlusion technique, while 230 patients received regular TAR with FET procedure.

Surgical Technique of ABO Technique

A four-branched graft (Terumo; Vascutek Limited, Renfrewshire, UK) was trimmed, and the 40M All AD aortic balloon (Coda Balloon Catheter; Cook Incorporated, Bloomington, IN, USA) was inserted into an 18F Gore sheath (W.L. Gore & Associates, Inc., Flagstaff, AZ, USA), which had already been inserted into the graft. Arterial cannulation was performed through the right axillary and femoral arteries with a bifurcated arterial line from one central perfusion. Cardiopulmonary bypass (CPB) was stopped at 28°C which was the target nasopharyngeal temperature. After clamping the proximal innominate artery, the anterograde selective cerebral perfusion (ASCP) was obtained at a rate of 5–10 ml/kg/min through the right axillary artery cannula. After the Cronus stent elephant trunk (diameter: 26 or 28 mm; length: 100 or 120 mm; Cronus, MicroPort Endovascular



Shanghai Co., Ltd., Shanghai, China) was released in the true lumen of the descending thoracic aorta (DTA).

The sheathed aortic balloon was deployed into the stent-graft, acknowledging that any part the balloon could be constricted by the solid metal stent. The balloon was inflated via injection of 40 ml saline to compress the stent-graft. Once the balloon was fixed, lower body perfusion was restarted through the right femoral artery cannula along with ASCP through the right axillary artery cannula. The CPB flow restarted and gradually increased to 50% of the total flow. The lower body CA was $6.3 \pm 5.7 \min$ (**Figure 1A**). During conventional TAR with FET surgery, lower body CA is required until distal anastomosis (suture of the wall of the DTA, the proximal wall of the stent-graft, and the distal wall of trifurcated graft) is completed, before CPB can be restarted and gradually increased to 50% of the total flow (**Figure 1B**).

For DeBakey type III patients, with an ascending aortic aneurysm and/or intracardiac diseases (such as aortic valve regurgitation or atrial septal defect), it is possible to treat all diseases during a one-stage operation by performing TAR with FET surgery. The treatment of AD in the DTA and/or left subclavian artery is more effective in the long term compared with thoracic endovascular aortic repair. The chronicity of AD and the aortic pathology of the patients were recorded in the patient records. After matching, both the aortic pathology and chronicity classifications of AD indicated that the conventional group was more, or at least as likely to be, reasonable as the conventional group before matching. The left common carotid artery was anastomosed first, and then perfusion through both carotid arteries could be realized. The rewarming process was subsequently started (**Figure 1C**).

Data Collection and Statistical Analysis

Major complications and clinical endpoints were recorded according to the consensus statement from the IAASSG (5). Specifically, postoperative acute kidney injury (AKI) was defined as a serum creatinine (Scr) volume over 1.5 times that of the normal value (<133 μ mol/L). Liver injury was defined as transaminase concentrations 1.5 times greater than those of the corresponding upper range of their normal values [alanine transaminase (ALT) <40 U/L, aspartate transaminase

Abbreviations: ABO, aortic balloon occlusion; TAR, total arch replacement; FET, frozen elephant trunk; CA, circulatory arrest; RBC, red blood cell; AD, aortic dissection; IAASSG, international aortic arch surgery study group; CPB, cardiopulmonary bypass; ASCP, anterograde selective cerebral perfusion; DTA, descending thoracic aorta; AKI, acute kidney injury; CRRT, continuous renal replacement therapy.

(AST) <55 U/L] for more than 48 h. The clinical examinations were all collected preoperatively. In addition, continuous renal replacement therapy (CRRT) is indicated when the patient has a urine volume <0.5 ml/(h-kg) for more than 6 h or a pH <7.2 and residual base <-8 mmol/L or serum potassium >6.0 mmol/L or a 2- to 2.9-fold increase in serum creatinine value from baseline levels.

Following the surgical procedure, data regarding patient transfer to the intensive care unit (ICU) was collected. (0), twice on postoperative days 1 to 3 (1, 1.5, 2, 2.5, 3), midtime point of ICU if the patient stayed in ICU more than 4 days (Mid), the last examination before transferred out from ICU (ICU), the first examination after transfer out from ICU to ward (Ward), and the last examination before discharge (Discharge). These items were considered as both time-matched comparisons during the first three postoperative days and eventmatched comparisons obliterating time (preoperative, transfer out of ICU, and fully recovered discharge values) to achieve maximum power. Categorical variables were compared using the χ^2 test. Continuous variables were presented as mean \pm SD; ALT and AST were presented as mean \pm SEM. All parameters related to time also included the median (M) and interquartile range. A normality test between the two groups was performed on the continuous variables. If the variable satisfied the normality test (Shapiro-Wilk test), the statistical analysis was evaluated with a t-test. If the variable failed the Shapiro-Wilk test, it was evaluated by the Mann-Whitney U-test. Clinical data were depicted in the figures to show the characteristics of the trends of perioperative alteration between the two groups. Due to fluctuating values, no statistical analyses could be performed to compare differences between time points and multiple comparison corrections to obtain p-values. According to the basic characteristics of comparison groups, once there are significant differences of potential confounding variables found between groups, propensity score matching will be conducted to control the confounding factors and reduce the risk of potential biases. The propensity score will be generated through a multivariable logistic regression analysis model and be applied to create 1:1 matching pairs of the conservative group and the innovative group. A nearest neighbor matching algorithm without a caliper method will be used. All the statistical analysis in the study will be performed using SPSS software (version 22.0; IBM-SPSS Inc., Armonk, NY, USA).

RESULTS

Baseline Characteristics and Early Outcomes

The baseline demographic and clinical characteristics of the patients are listed in **Table 1**. Several differences are evident: the aortic balloon occlusion (ABO) group is associated with older age, less cardiac surgery history, and inconsistently distributed CPB time, all of which were included in the propensity score matching. The matched cohorts consisted of mostly male patients, aged 49.9 \pm 12.2 and 49.6 \pm 10.0 years, respectively (p = 0.547). The most common aortic pathology type present in

both cohorts was the AD in the acute stage (<72 h). All patients had similar smoking, cardiovascular disease, and cerebrovascular event histories. There were no statistically significant differences between patients having aortic arch lesions with a proximal extension to the aortic root (43.1 vs. 42.3%, p = 0.827) or distal extension to iliac arteries (59.4 vs. 63.4%, p = 0.513) in the ABO group and the conventional group, respectively. In addition to TAR with FET operations, the concomitant root operations and coronary artery bypass grafts were performed according to the related indications in a similar proportion in both groups. Duration of lower body CA and ASCP time was significantly lower in the ABO group compared with the conventional group (1 ± 4.2 min and 6.3 ± 5.7 min, p < 0.001, respectively), whereas the nasal temperature was greater (25.5 ± 1.0°C and 27.4 ± 1.1°C, respectively) during CA.

After propensity score matching, the 30-day mortality of the ABO group and the conventional group was 4.6 and 10.8% (p = 0.063), respectively. Although the 30-day mortality of the ABO group was lower in the ABO group, the difference was not statistically significant. The ICU stay time was similar in both groups, 119.9 ± 106.3 h vs. 131.1 ± 150.0 h (p = 0.415), as was the postoperative in-hospital stay time, 11.8 ± 5.4 days vs. 12.3 ± 6.7 days (p = 0.900). The incidence of stroke (3.1 vs. 4.6%, p = 0.519), temporal paraplegia (2.3 vs. 5.4%, p = 0.197), and delirium (3.1 vs. 7.7%, p = 0.099) were also similar in the ABO group compared with the conventional group, respectively.

Renal System Results

Volumes of Scr and urine, and CRRT were found to be the most common and therefore reliable parameters to evaluate the postoperative AKI. Patients with oliguria or anuria who underwent CRRT had the worse prognosis. Scr was a key indicator when evaluating the underlying AKI incidence. The ABO technique significantly reduced the incidence of postoperative AKI (23.1 vs. 38.5%, p = 0.007) and CRRT (7.7 vs. 16.2%, p = 0.037) in the ABO group compared with the conventional group, respectively.

To further investigate the in-hospital recovery course of renal function and explore the benefits of ABO technique, we examined the patients' blood examination results. Scr value reflects whether postoperative renal function recovery is good or poor. Blood urea nitrogen values were similar in pattern to those of Scr; however, the blood urea nitrogen peak appeared later. Uric acid (UA) was also recorded from the renal function examination, and it tended to decrease. The decrease in postoperative UA levels may also reflect renal function recovery (**Figure 2**).

Postoperative Bleeding

The operation time after CPB was significantly shorter in the ABO group than the conventional group (128.8 \pm 54.3 min vs. 167.6 \pm 73.1 min, p < 0.001). The propensity-matched comparisons showed that the ABO group had a lower operative time and lower volumes of red blood cell (RBC) and platelet transfusions.

RBC transfusion is necessary when a patient's hemoglobin concentration is below 80 g/L following cardiac surgery (6). More than 50% of patients received at least one 1

TABLE 1 | Preoperative and operative details.

<i>l</i> ariables	Aortic balloon occlusion ($N = 130$)	Conventional before matching ($N = 230$)	Р	Conventional after matching ($N = 130$)	Р
Age	49.84 ± 12.21	48.00 ± 10.27	0.087	49.63 ± 9.97	0.547
Male	99 (76.15)	173 (75.22)	0.843	103 (79.23)	0.551
Smoke history	74 (56.92)	130 (56.52)	0.941	76 (58.46)	0.802
Mild	5 (3.85)	6 (2.61)		6 (4.62)	0.005
Heavy	69 (53.08)	124 (53.91)	0.806	70 (53.85)	0.935
Chronic obstructive pulmonary disease	6 (4.62)	2 (0.87)	0.021	2 (1.54)	0.151
Cardiac surgery history	2 (1.54)	15 (6.52)	0.032	3 (2.31)	0.652
Coronary artery disease history	13 (10.00)	24 (10.43)	0.896	14 (10.77)	0.839
Myocardial infarction history ¹	1 (0.77)	6 (2.61)	0.225	4 (3.08)	0.176
Cerebrovascular accident ²	11 (8.46)	23 (10.00)	0.632	12 (9.23)	0.827
Marfan syndrome	6 (4.62)	22 (9.57)	0.092	7 (5.38)	0.776
Fime of onset (d)	86.04 ± 401.33 2.83 (1.23–11.90)	51.26 ± 259.97 2.52 (1.07–9.06)	0.373	53.27 ± 261.73 2.72 (1.01–10.62)	0.336
Classification based on chronicity N (%)				
Acute, <7 d (h)	50.47 ± 37.92 35.25 (23.48–66.88) 87 (66.92)	51.96 ± 42.41 38.32 (22.48–69.56) 168 (73.04)	0.228 (0.220)	48.62 ± 37.11 31.83 (19.62–69.70) 93 (71.54)	0.432 (0.420)
Subacute, 7–30 d (d)	15.10 ± 5.54 14.07 (10.40–19.11) 23 (17.69)	14.28 ± 5.71 12.28 (9.4–17.58) 20 (8.70)	0.638 (0.011)	14.06 ± 5.94 12.23 (10.01–16.56) 13 (10.00)	0.017 (0.073)
Chronic, >30 d (d)	556.21 ± 933.51 160 (54.5–372.5) 20 (15.38)	265.21 ± 565.71 97 (40–213) 42 (18.26)	0.161 (0.488)	271.46 ± 565.79 84.5 (35.75–223.25) 24 (18.46)	0.013 (0.508)
Aortic pathology	, , ,	, , ,		· · · ·	
Aneurysm	7 (5.38)	9 (3.91)		7 (5.83)	
Aortic dissection	123 (94.62)	221 (96.09)	0.515	123 (94.62)	1
Aortic dissection classification ³	N (N/123)	N (N/221)		N (N/123)	
Stanford type A (DeBakey I&II)	105 (85.37)	208 (94.12)	0.007	119 (91.54)	0.002
Stanford type B (DeBakey III)	7 (5.69)	4 (1.81)	0.050	0 (0)	0.007
Stanford type NANB	11 (8.94)	9 (4.04)	0.064	4 (3.25)	0.062
Aortic dissection involvement	N (N/123)	N (N/221)		N (N/123)	
Root	53 (43.09)	93 (42.08)	0.856	55 (42.31)	0.797
Ascending	105 (85.37)	208 (94.12)	0.007	119 (91.54)	0.002
Arch	123 (100)	221 (100)	1	123 (100)	1
Total/proximal	116 (94.31)	217 (98.19)		123 (100)	
Left subclavian artery or distal	7 (5.69)	4 (1.81)	0.050	0 (0)	0.007
Thoracic descending	115 (93.50)	207 (93.67)		116 (94.31)	0.790
Total abdominal	84 (68.29)	143 (64.17)	0.951	84 (68.29)	1
lliac	73 (59.35)	135 (61.09)	0.752	78 (63.41)	0.513
Aortic diameter on CT	()	()			
Ascending aorta	45.81 + 9.96	47.53 + 12 21	0.274	45.85 + 11 60	0 736
Descending aorta	31.26 + 6.38	34.03 ± 9.44	0.100	32.84 + 7.06	0.492
Branch aortic dissection involvement	N (N/123)	N (N/221)		N (N/123)	5
Coronary (total)	26 (21 14)	56 (25.34)	0,381	32 (26 02)	0.367
Left coronary artery	11 (8.94)	20 (9 05)	0.974	11 (8.94)	1
Left coronary artery only	1 (0 77)	4 (1 74)	0.450	3 (2 31)	0.314
Right coronary artery	25 (20, 33)	52 (23 53)	0 494	29 (23 58)	0.538
Right coronary artery only	15 (11 54)	36 (15 65)	0.282	21 (16 15)	0.000
Coronary (Both)	10 (7 69)	16 (6 96)	0.202	8 (6 15)	0.201
	60 (49 79)	110 (40 77)	0.100	67 (54 47)	0.020
LATT renal arten/ involvement				/ / .	11.11/

(Continued)

TABLE 1 | Continued

Right renal artery involvement 38 (30.89) 71 (32.13) 0.814 41 (33.33) 0.682 Right renal artery evidence of stenosis 17 (13.82) 27 (12.22) 0.669 14 (11.38) 0.564 Aortic roct operation 53 (40.77) 66 (29.57) 44 (33.85) 65 (41.74) 53 (40.77) Bepair or plasty 53 (40.77) 66 (29.57) 44 (33.85) 0.388 Wheat 8 (6.15) 10 (4.55) 5 (3.45) 0.388 David 1 (0.77) 4 (1.74) 3 (2.31) Conconstant coronary artery bypass graft 18 (13.85) 25 (10.87) -0.001 14 (10.77) c0.001 (CABG) 18 (13.85) 25 (10.87) -0.001 2 (1.54) -0.001 2 (1.54) -0.001 Cardiopulmonary bypass time 185.20 \pm 66.99 188.87 \pm 89.25 0.152 188.12 \pm 74.35 0.245 Cardiopulmonary bypass time 118.20 \pm 56.89 118.85 0.034 112.95 \pm 38.75 0.073 Cardiopulmonary bypass time 118.42 \pm 2.42 \pm 113.05 39.43 \pm 74.35 0.245 175 (14	Variables	Aortic balloon occlusion (<i>N</i> = 130)	Conventional before matching ($N = 230$)	Р	Conventional after matching ($N = 130$)	Р
Right renal artery evidence of stenosis 17 (13.82) 27 (12.22) 0.669 14 (11.38) 0.564 Aortic root operation None 41 (31.54) 96 (41.74) 53 (40.77) 68 (29.57) 44 (33.85) 0.388 Bental 27 (20.77) 52 (22.61) 0.158 25 (19.23) 0.388 Wheat 8 (6.15) 10 (4.35) 5 (3.85) 0.013 3 (2.31) Concomitant coronary artery bypass graft 18 (13.85) 25 (10.87) -0.001 2 (1.54) -0.001 Salvage CABG 0 (0) 5 (2.17) -0.001 2 (1.54) -0.001 Correlation time 396.95 ± 85.42 409.76 ± 118.77 -0.001 2 (1.54) -0.001 Cardiopulmonary bypass time 18 (2.52) ± 56.99 18.857 ± 89.25 0.152 18.81 ± 74.35 0.245 Cardiopulmonary bypass time 19.34 ± 38.25 11.305 ± 39.53 0.034 112.95 ± 38.75 0.073 Cardiopulmonary bypass time 19.34 ± 38.25 11.305 ± 39.53 0.031 112.95 ± 38.75 0.073 Cardiopulmonary bypass time	Right renal artery involvement	38 (30.89)	71 (32.13)	0.814	41 (33.33)	0.682
Addition to operation None 41 (31.54) 96 (41.74) 53 (40.77) Repair or plasty 53 (40.77) 68 (29.57) 44 (33.85) 56 (3.85) Bental 27 (20.77) 52 (22.61) 0.158 25 (19.23) 0.388 Wheat 8 (6.15) 10 (4.35) 5 (3.85) 0.000 0.001 0.001 0.001 0.001 0.001 0.001 0.001 0.001 0.001 0.001 0.001 0.001 0.001 0.001 0.001 0.001 0.001 0.001 0.001 0.001 0.001 0.001 0.001 0.001 0.001 0.001 0.001 0.001 0.001 0.001 0.001 0.001 0.001 0.001 0.001 0.001 0.001 0.001 0.001 0.001 0.001 0.001 0.001 0.001 0.001 0.001 0.001 0.001 0.001 0.001 0.001 0.001 0.001 0.001 0.001 0.001 0.001 0.001 0.001 0.001 0.001	Right renal artery evidence of stenosis	17 (13.82)	27 (12.22)	0.669	14 (11.38)	0.564
None 41 (31.54) 96 (41.74) 53 (40.77) Pepair or plasty 53 (40.77) 68 (29.57) 44 (33.65) Bental 27 (20.77) 52 (22.61) 0.158 25 (19.23) 0.388 Wheat 8 (6.15) 10 (4.35) 5 (3.85) 0.000 3 (2.31) Concomitant coronary artery bypass graft 18 (13.85) 25 (10.87) -0.001 2 (1.54) -0.001 Planned CABG 0 (0) 5 (2.17) -0.001 2 (1.54) -0.001 -0.001 Operation time 396.95 ± 85.42 409.76 ± 118.77 0.445 402.64 ± 113.06 0.872 379 (337-430) 395 (330-463) -394 (321-458) -0.01 2 (1.54) -0.01 Cardiopulmonary bypass time 119.34 ± 36.25 113.05 ± 39.53 0.152 188.12 ± 74.35 0.031 Calmp time 119.34 ± 36.25 113.05 ± 39.53 0.034 112.95 ± 38.75 0.073 Circulatory arrest duration 6.33 ± 5.74 17.24 ± 4.36 -0.001 30.62 ± 10.03 -0.001 fime 3 (46-62)	Aortic root operation					
Repair or plasty $53 (40.77)$ $68 (29.57)$ $44 (33.85)$ Bentall $27 (20.77)$ $52 (22.61)$ 0.158 $25 (19.23)$ 0.388 Wheat $8 (6.15)$ $10 (4.35)$ $5 (3.85)$ 0.301 $3 (2.31)$ 0.001 David $1 (0.77)$ $4 (1.74)$ $3 (2.31)$ 0.001 $0.612 (2.13)$ 0.713 (CABG) $18 (13.85)$ $25 (10.87)$ 0.001 $14 (10.77)$ $2 (1.54)$ 0.001 Planned CABG $18 (13.85)$ $25 (10.87)$ 0.001 $14 (10.77)$ 0.001 Salvage CABG $0 (0)$ $5 (2.17)$ 0.445 402.64 ± 113.06 0.872 Operation time $396 (337-430)$ $396 (330-463)$ $394 (321-458)$ 0.245 Cardiopulmonary bypass time 185.20 ± 56.99 188.57 ± 89.25 0.152 188.12 ± 74.35 0.245 Clamp time 19.34 ± 36.25 113.05 ± 39.53 0.034 112.95 ± 38.75 0.73 Cologing time 20.90 ± 7.26 30.33 ± 9.78 <0.001 30.52 ± 10.03 <0.001 $20 (16-24)$ $29 (23-36)$ $29 (23-36)$ $29 (23-36)$ $29 (23-36)$ $29 (23-36)$ Cinculatory arrest duration $5 (3 + 17.24 \pm 4.36)$ <0.001 17.09 ± 4.18 <0.001 $114 (4912.1)$ $71 (14.75-19)$ $71 (14.75-19)$ $32 (26-39)$ $32 (26-39)$ Rewarming time 39.88 ± 14.51 33.28 ± 10.01 <0.001 33.88 ± 10.92 <0.001 $119 (48-137)$ $157 (123-199)$ $156 (126-199)$ $156 (126-199)$ <td>None</td> <td>41 (31.54)</td> <td>96 (41.74)</td> <td></td> <td>53 (40.77)</td> <td></td>	None	41 (31.54)	96 (41.74)		53 (40.77)	
Bentall27 (20.77)52 (22.61)0.15825 (19.23)0.388Wheat8 (6.15)10 (4.35)5 (3.65)David1 (0.77)4 (1.74)3 (2.31)Concomitant coronary artery bypass graft18 (13.85)03 (13.04)0.83016 (12.31)CABG18 (13.85)25 (10.87) -0.001 14 (10.77)Salvage CABG0 (0)5 (2.17) -0.001 14 (10.77)Operation time396.95 ± 85.42409.76 ± 118.77 0.445 402.64 ± 113.06Operation time185.20 ± 56.99188.57 ± 89.250.152188.12 ± 74.350.245Cardiopulmonary bypass time185.20 ± 56.99188.57 ± 89.250.152188.12 ± 74.350.245Cardiopulmonary bypass time185.20 ± 56.91118.05 ± 39.530.034112.95 ± 38.750.73Clamp time19.03 ± 36.25113.05 ± 39.530.034112.95 ± 38.750.73Cooling time20.90 ± 7.2630.33 ± 9.78<0.001	Repair or plasty	53 (40.77)	68 (29.57)		44 (33.85)	
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	Bentall	27 (20.77)	52 (22.61)	0.158	25 (19.23)	0.388
$ \begin{array}{ c c c c c c } \mbox{David} & 1 (0.7) & 4 (1.74) & 3 (2.31) \\ \hline \mbox{Concomitant coronary artery bypass graft} & 18 (13.85) & 30 (13.04) & 0.830 & 16 (12.31) & 0.713 (CABG) & & & & & & & & & & & & & & & & & & &$	Wheat	8 (6.15)	10 (4.35)		5 (3.85)	
$ \begin{array}{c c} Concomitant coronary artery bypass graft \\ (CABG) & 18 (13.85) & 25 (10.87) \\ Planned CABG & 18 (13.85) & 25 (10.87) \\ Salvage CABG & 0 (0) & 5 (2.17) \\ Operation time & 396.95 \pm 85.42 & 409.76 \pm 118.77 \\ Operation time & 396.95 \pm 85.42 & 409.76 \pm 118.77 \\ Operation time & 185.20 \pm 56.99 & 188.57 \pm 89.25 \\ Cardiopulmonary bypass time & 185.20 \pm 56.99 & 188.57 \pm 89.25 \\ 175 (148-201) & 162 (141-209) \\ Clamp time & 119.34 \pm 36.25 & 113.05 \pm 39.53 \\ 114 (94-143) & 109 (89-131) \\ Cooling time & 20.90 \pm 7.26 & 30.33 \pm 9.78 \\ 0.001 & 30.52 \pm 10.03 \\ 0.001 & 20 (16-24) & 29 (23-36) \\ 0.001 & 30.52 \pm 10.03 \\ 0.001 & 30.38 \pm 10.92 \\ 0.001 & 5 (3-7) & 17 (14-20) \\ 0.001 & 33.38 \pm 10.92 \\ 0.001 & 5 (3-7) & 17 (14-20) \\ 0.001 & 33.38 \pm 10.92 \\ 0.001 & 5 (3-7) & 17 (14-20) \\ 0.001 & 33.38 \pm 10.92 \\ 0.001 & 5 (3-7) & 17 (14-20) \\ 0.001 & 33.84 \pm 10.92 \\ 0.001 & 5 (3-7) & 17 (14-20) \\ 0.001 & 33.84 \pm 10.92 \\ 0.001 & 5 (3-7) & 17 (14-20) \\ 0.001 & 33.84 \pm 10.92 \\ 0.001 & 5 (3-7) & 17 (14-7-19) \\ 0.001 & 33.84 \pm 10.92 \\ 0.001 & 5 (3-62) & 63 (53-74) \\ 0.001 & 65.98 \pm 19.60 \\ 0.001 & 65.98 \pm 19.60 \\ 0.001 \\ 0.001 & 167.55 \pm 73.08 \\ 0.001 \\ 0.001 & 167.55 \pm 73.08 \\ 0.001 \\ 0.001 & 167.55 \pm 73.08 \\ 0.001 \\ 0.001 & 19 (8-137) \\ 19 (8-137) & 157 (123-199) \\ 157 (123-199) \\ 157 (123-199) \\ 156 (126-199) \\ 156 (126-199) \\ 156 (126-199) \\ 156 (126-199) \\ 156 (126-199) \\ 156 (126-199) \\ 156 (126-199) \\ 156 (126-199) \\ 156 (126-199) \\ 156 (126-199) \\ 156 (126-199) \\ 156 (126-199) \\ 156 (126-199) \\ 156 (126-199) \\ 156 (126-199) \\ 156 (126-199) \\ 156 (126-199) \\ 156 (126-199) \\ 156 (126-199) \\ 156 (126-199) \\ 156 (126-199) \\ 156 (126-199) \\ 156 (126-199) \\ 156 (126-199) \\ 156 (126-199) \\ 156 (126-199) \\ 156 (126-199) \\ 156 (126-199) \\ 156 (126-199) \\ 156 (126-199) \\ 156 (126-199) \\ 156 (126-199) \\ 156 (126-199) \\ 156 (126-199) \\ 156 (126-199) \\ 156 (126-199) \\ 156 (126-199) \\ 156 (126-199) \\ 156 (126-199) \\ 156 (126-199) \\ 156 (126-199) \\ 156 (126-199) \\ 156 (126-199) \\ 156 (126-199) \\ 156 (126-199) \\ 156 (126-199) \\ 156 (126-19)$	David	1 (0.77)	4 (1.74)		3 (2.31)	
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	Concomitant coronary artery bypass graft (CABG)	18 (13.85)	30 (13.04)	0.830	16 (12.31)	0.713
Salvage CABG0 (0)5 (2.17) $2 (1.54)$ $2 (1.54)$ Operation time396.95 ± 85.42409.76 ± 118.770.445402.64 ± 113.060.872379 (337-430)395 (330-463)394 (321-458)0.872Cardiopulmonary bypass time185.20 ± 56.99188.57 ± 89.250.152188.12 ± 74.350.245175 (148-201)162 (141-209)159 (141-211)0.073119 (141-211)0.073Clamp time119.34 ± 36.25113.05 ± 39.530.034112.95 ± 38.750.073114 (94-143)109 (89-131)107.5 (85-132.25)0.01520 (16-24)29 (23-36)Cooling time20.90 ± 7.2630.33 ± 9.78<0.001	Planned CABG	18 (13.85)	25 (10.87)	<0.001	14 (10.77)	<0.001
$ \begin{array}{c} \mbox{Operation time} & 396.95 \pm 85.42 & 409.76 \pm 118.77 & 0.445 & 402.64 \pm 113.06 & 0.872 \\ 379 (337-430) & 395 (330-463) & 394 (321-458) \\ 394 (321-458) & 394 (321-458) & 0.245 \\ 175 (148-201) & 162 (141-209) & 159 (141-211) \\ 162 (141-209) & 109 (89-131) & 107.5 (85-132.25) \\ 107.5 (85-132.25) & 0.073 \\ 114 (94-143) & 109 (89-131) & 107.5 (85-132.25) \\ 107.5 (85-132.25) & 0.001 \\ 20 (16-24) & 29 (23-36) & 29 (23-36) \\ 20 (16-24) & 29 (23-36) & 29 (23-36) \\ 20 (16-24) & 29 (23-36) & 29 (23-36) \\ 20 (16-24) & 29 (23-36) & 29 (23-36) \\ 20 (16-24) & 29 (23-36) & 29 (23-36) \\ 20 (16-24) & 29 (23-36) & 29 (23-36) \\ \hline \\ \mbox{Circulatory arrest duration} & 6.33 \pm 5.74 & 17.24 \pm 4.36 & <0.001 & 17.09 \pm 4.18 & <0.001 \\ 5 (3-7) & 17 (14-20) & 17 (14.75-19) \\ \hline \\ \mbox{Antegrade selective cerebral perfusion} & 39.88 \pm 14.51 & 33.28 \pm 10.01 & <0.001 & 33.38 \pm 10.92 & <0.001 \\ \mbox{time} & 37 (31-47) & 32 (26-38) & 32 (26-39) \\ \hline \\ \mbox{Rewarming time} & 53.64 \pm 17.51 & 65.58 \pm 19.52 & <0.001 & 65.98 \pm 19.60 & <0.001 \\ \mbox{time} & 37 (31-47) & 32 (26-38) & 32 (26-39) \\ \hline \\ \mbox{Post cardiopulmonary bypass time} & 128.78 \pm 54.29 & 166.10 \pm 66.00 & <0.001 & 167.55 \pm 73.08 & <0.001 \\ \mbox{time} & 19 (98-137) & 157 (123-199) & 156 (126-199) \\ \hline \\ \mbox{Tet temperature when the circulatory arrest was commenced (°C) \\ \hline \\ \mbox{Nasopharyngeal} & 27.41 \pm 1.06 & 25.37 \pm 1.34 & <0.001 & 25.45 \pm 0.96 & <0.001 \\ \mbox{Rectal} & 29.00 \pm 1.91 & 28.46 \pm 2.55 & 0.015 & 28.61 \pm 2.53 & <0.001 \\ \hline \ \mbox{time} & 29.00 \pm 1.91 & 28.46 \pm 2.55 & 0.015 & 28.61 \pm 2.53 & <0.001 \\ \hline \mbox{time} & 29.00 \pm 1.91 & 28.46 \pm 2.55 & 0.015 & 28.61 \pm 2.53 & <0.001 \\ \hline \mbox{time} & 29.00 \pm 1.91 & 28.46 \pm 2.55 & 0.015 & 28.61 \pm 2.53 & <0.001 \\ \hline \mbox{time} & 29.00 \pm 1.91 & 28.46 \pm 2.55 & 0.015 & 28.61 \pm 2.53 & <0.001 \\ \hline \mbox{time} & 29.00 \pm 1.91 & 28.46 \pm 2.55 & 0.015 & 28.61 \pm 2.53 & <0.001 \\ \hline \mbox{time} & 29.00 \pm 1.91 & 28.46 \pm 2.55 & 0.015 & 28.61 \pm 2.53 & <0.001 \\ \hline \mbox{time} & 29.00 \pm 1.91 & 28.46 \pm 2.55 & 0.015 & 28.61 \pm 2.53 & $	Salvage CABG	O (O)	5 (2.17)		2 (1.54)	
$ \begin{array}{c} \mbox{Cardiopulmonary bypass time} & 185.20 \pm 56.99 & 188.57 \pm 89.25 & 0.152 & 188.12 \pm 74.35 & 0.245 \\ 175 (148-201) & 162 (141-209) & 159 (141-211) & 159 (141-211) & 119 (141-211) & 119 (141-211) & 119 (141-211) & 110 (141-211) & 110 (141-211) & 110 (141-211) & 110 (141-211) & 110 (141-211) & 110 (141-211) & 110 (141-211) & 110 (141-211) & 110 (141-211) & 110 (141-211) & 110 (141-211) & 110 (141-211) & 110 (141-211) & 110 (141-211) & 110 (141-211) & 110 (141-211) & 110 (141-211) & 110 (141-211) & 110 (141-211) & 110 (141-211) & 110 (141-211) & 110 (141-211) & 110 (141-211) & 110 (141-211) & 110 (141-211) & 110 (141-211) & 110 (141-211) & 110 (141-211) & 110 (141-211) & 110 (141-211) & 110 (141-211) & 110 (141-211) & 110 (141-211) & 110 (141-211) & 110 (141-211) & 110 (141-211) & 110 (141-211) & 110 (141-211) & 110 & 110 (141-211) & 110 (141-211) & 110 & 110 (141-211) & 110 & 110 & 110 & 110 & 110 & 110 & 110 & 110 & 110 & 110 & 110 & 110 & 110 & 110 & 110 & 110 & 110 & 110 & 110 & 110 & 110 & 110 & 110 & 110 & 110 & 110 & 110 & 110 & 110 & 110 & 110 & 110 & 110 & 110 & 110 & 110 & 110 & 110 & 110 & 110 & 110 & 110 & 110 & 110 & 110 & 110 & 110 & 110 & 110 & 110 & 110 & 110 & 110 & 110 & 110 & 110 & 110 & 110 & 110 & 110 & 110 & 110 & 110 & 110 & 110 & 110 & 110 & 110 & 110 & 110 & 110 & 110 & 110 & 110 & 110 & 110 & 110 & 110 & 110 & 110 & 110 & 110 & 110 & 110 & 110 & 110 & 110 & 110 & 110 & 110 & 110 & 110 & 110 & 110 & 110 & 110 & 110 & 110 & 110 & 110 & 110 & 110 & 110 & 110 & 110 & 110 & 110 & 110 & 110 & 110 & 110 & 110 & 110 & 110 & 110 & 110 & 110 & 110 & 110 & 110 & 110 & 110 & 110 & 110 & 110 & 110 & 110 & 110 & 110 & 110 & 110 & 110 & 110 & 110 & 110 & 110 & 110 & 110 & 110 & 110 & 110 & 110 & 110 & 110 & 110 & 110 & 110 & 110 & 110 & 110 & 110 & 110 & 110 & 110 & 110 & 110 & 110 & 110 & 110 & 110 & 110 & 110 & 110 & 110 & 110 & 110 & 110 & 110 & 110 & 110 & 110 & 110 & 110 & 110 & 110 & 110 & 110 & 110 & 110 & 110 & 110 & 110 & 110 & 110 & 110 & 110 & 110 & 110 & 110 & 110 & 110 & 110 & 11$	Operation time	396.95 ± 85.42 379 (337–430)	409.76 ± 118.77 395 (330–463)	0.445	402.64 ± 113.06 394 (321–458)	0.872
$\begin{array}{cccccccccccccccccccccccccccccccccccc$	Cardiopulmonary bypass time	185.20 ± 56.99 175 (148–201)	188.57 ± 89.25 162 (141–209)	0.152	188.12 ± 74.35 159 (141–211)	0.245
$ \begin{array}{cccc} \mbox{Cooling time} & 20.90 \pm 7.26 & 30.33 \pm 9.78 \\ 20 (16-24) & 29 (23-36) & 29 (23-36) & 29 (23-36) \\ \mbox{Circulatory arrest duration} & 6.33 \pm 5.74 & 17.24 \pm 4.36 \\ 5 (3-7) & 17 (14-20) & 17 (14.75-19) & 17 (14.75-19) \\ \mbox{Antegrade selective cerebral perfusion} & 39.88 \pm 14.51 & 33.28 \pm 10.01 & <0.001 & 33.38 \pm 10.92 & <0.001 \\ \mbox{time} & 37 (31-47) & 32 (26-38) & 32 (26-39) & 32 (26-39) & 32 (26-39) & 32 (26-39) & 32 (26-39) & 32 (26-39) & 32 (26-39) & 32 (26-39) & 32 (26-39) & 32 (26-39) & 32 (26-39) & 32 (26-39) & 32 (26-39) & 32 (26-39) & 32 (26-39) & 32 (26-39) & 32 (26-39) & 32 (26-39) & 32 (26-39) & 32 (26-39) & 32 (26-39) & 32 (26-39) & 32 (26-39) & 32 (26-39) & 32 (26-39) & 32 (26-39) & 32 (26-39) & 32 (26-39) & 32 (26-39) & 32 (26-39) & 32 (26-39) & 32 (26-39) & 32 (26-39) & 32 (26-39) & 32 (26-39) & 32 (26-39) & 32 (26-39) & 32 (26-39) & 32 (26-39) & 32 (26-39) & 32 (26-39) & 32 (26-39) & 32 (26-39) & 32 (26-39) & 32 (26-39) & 32 (26-39) & 32 (26-39) & 32 (26-39) & 32 (26-39) & 32 (26-39) & 32 (26-39) & 32 (26-39) & 32 (26-39) & 32 (26-39) & 32 (26-39) & 32 (26-39) & 32 (26-39) & 32 (26-39) & 32 (26-39) & 32 (26-39) & 32 (26-39) & 32 (26-39) & 32 (26-39) & 32 (26-39) & 32 (26-39) & 32 (26-39) & 32 (26-39) & 32 (26-39) & 32 (26-39) & 32 (26-39) & 32 (26-39) & 32 (26-39) & 32 (26-39) & 32 (26-39) & 32 (26-39) & 32 (26-39) & 32 (26-39) & 32 (26-39) & 32 (26-39) & 32 (26-39) & 32 (26-39) & 32 (26-39) & 32 (26-39) & 32 (26-39) & 32 (26-39) & 32 (26-39) & 32 (26-39) & 32 (26-39) & 32 (26-39) & 32 (26-39) & 32 (26-39) & 32 (26-39) & 32 (26-39) & 32 (26-39) & 32 (26-39) & 32 (26-39) & 32 (26-39) & 32 (26-39) & 32 (26-39) & 32 (26-39) & 32 (26-39) & 32 (26-39) & 32 (26-39) & 32 (26-39) & 32 (26-39) & 32 (26-39) & 32 (26-39) & 32 (26-39) & 32 (26-39) & 32 (26-39) & 32 (26-39) & 32 (26-39) & 32 (26-39) & 32 (26-39) & 32 (26-39) & 32 (26-39) & 32 (26-39) & 32 (26-39) & 32 (26-39) & 32 (26-39) & 32 (26-39) & 32 (26-39) & 32 (26-39) & 32 (26-39) & 32 (26-39) & 32 (26-39) & 32 (26-39) & 32 (2$	Clamp time	119.34 ± 36.25 114 (94–143)	113.05 ± 39.53 109 (89–131)	0.034	112.95 ± 38.75 107.5 (85–132.25)	0.073
Circulatory arrest duration 6.33 ± 5.74 $5 (3-7)$ 17.24 ± 4.36 $17 (14-20)$ <0.001 17.09 ± 4.18 $17 (14.75-19)$ <0.001 Antegrade selective cerebral perfusion 39.88 ± 14.51 $37 (31-47)$ 33.28 ± 10.01 $32 (26-38)$ <0.001 33.38 ± 10.92 $32 (26-39)$ <0.001 Rewarming time 53.64 ± 17.51 $53 (45-62)$ 65.58 ± 19.52 $63 (53-74)$ <0.001 65.98 ± 19.60 $64 (54-74.5)$ <0.001 Post cardiopulmonary bypass time 128.78 ± 54.29 $119 (98-137)$ 166.10 ± 66.00 $157 (123-199)$ <0.001 167.55 ± 73.08 $156 (126-199)$ <0.001 The temperature when the circulatory arrest was commenced (°C)Nasopharyngeal 27.41 ± 1.06 29.00 ± 1.91 25.37 ± 1.34 28.46 ± 2.55 <0.015 28.61 ± 2.53 28.61 ± 2.53 <0.001	Cooling time	20.90 ± 7.26 20 (16–24)	30.33 ± 9.78 29 (23–36)	<0.001	30.52 ± 10.03 29 (23–36)	<0.001
Antegrade selective cerebral perfusion 39.88 ± 14.51 33.28 ± 10.01 <0.001 33.38 ± 10.92 <0.001 time $37 (31-47)$ $32 (26-38)$ $32 (26-39)$ $32 (26-39)$ $32 (26-39)$ $32 (26-39)$ $32 (26-39)$ $32 (26-39)$ $32 (26-39)$ $32 (26-39)$ $32 (26-39)$ $32 (26-39)$ $32 (26-39)$ $32 (26-39)$ $32 (26-39)$ $32 (26-39)$ $32 (26-39)$ $32 (26-39)$ $32 (26-39)$ $32 (26-39)$ $32 (26-39)$ $32 (26-39)$ $32 (26-39)$ $32 (26-39)$ $32 (26-39)$ $32 (26-39)$ $32 (26-39)$ $32 (26-39)$ $32 (26-39)$ $32 (26-39)$ $32 (26-39)$ $32 (26-39)$ $32 (26-39)$ $32 (26-39)$ $32 (26-39)$ $32 (26-39)$ $32 (26-39)$ $32 (26-39)$ $32 (26-39)$ $32 (26-39)$ $32 (26-39)$ $32 (26-39)$ $32 (26-39)$ $32 (26-39)$ $32 (26-39)$ $32 (26-39)$ $32 (26-39)$ $32 (26-39)$ $32 (26-39)$ $32 (26-39)$ $32 (26-39)$ $32 (26-39)$ $32 (26-39)$ $32 (26-39)$ $32 (26-39)$ $32 (26-39)$ $32 (26-39)$ $32 (26-39)$ $32 (26-39)$ $32 (26-39)$ $32 (26-39)$ $32 (26-39)$ $32 (26-39)$ $32 (26-39)$ <td>Circulatory arrest duration</td> <td>6.33 ± 5.74 5 (3–7)</td> <td>17.24 ± 4.36 17 (14–20)</td> <td><0.001</td> <td>17.09 ± 4.18 17 (14.75–19)</td> <td><0.001</td>	Circulatory arrest duration	6.33 ± 5.74 5 (3–7)	17.24 ± 4.36 17 (14–20)	<0.001	17.09 ± 4.18 17 (14.75–19)	<0.001
Rewarming time 53.64 ± 17.51 65.58 ± 19.52 <0.001 65.98 ± 19.60 <0.001 Post cardiopulmonary bypass time 128.78 ± 54.29 166.10 ± 66.00 <0.001 167.55 ± 73.08 <0.001 The temperature when the circulatory arrest was commenced (°C) Nasopharyngeal 27.41 ± 1.06 25.37 ± 1.34 <0.001 25.45 ± 0.96 <0.001 Rectal 29.00 ± 1.91 28.46 ± 2.55 0.015 28.61 ± 2.53 <0.001	Antegrade selective cerebral perfusion time	39.88 ± 14.51 37 (31–47)	33.28 ± 10.01 32 (26–38)	<0.001	33.38 ± 10.92 32 (26–39)	<0.001
Post cardiopulmonary bypass time 128.78 ± 54.29 166.10 ± 66.00 <0.001 167.55 ± 73.08 <0.001 119 (98–137) 157 (123–199) 156 (126–199) 156 (126–199) 156 (126–199) <0.001	Rewarming time	53.64 ± 17.51 53 (45–62)	65.58 ± 19.52 63 (53–74)	<0.001	65.98 ± 19.60 64 (54–74.5)	<0.001
The temperature when the circulatory arrest was commenced (°C) Nasopharyngeal 27.41 ± 1.06 25.37 ± 1.34 <0.001 25.45 ± 0.96 <0.001 Rectal 29.00 ± 1.91 28.46 ± 2.55 0.015 28.61 ± 2.53 <0.001	Post cardiopulmonary bypass time	128.78 ± 54.29 119 (98–137)	166.10 ± 66.00 157 (123–199)	<0.001	167.55 ± 73.08 156 (126–199)	<0.001
Nasopharyngeal 27.41 ± 1.06 25.37 ± 1.34 <0.001 25.45 ± 0.96 <0.001 Rectal 29.00 ± 1.91 28.46 ± 2.55 0.015 28.61 ± 2.53 <0.001	The temperature when the circulatory a	arrest was commenced	l (°C)			
Rectal 29.00 ± 1.91 28.46 ± 2.55 0.015 28.61 ± 2.53 <0.001	Nasopharyngeal	27.41 ± 1.06	25.37 ± 1.34	<0.001	25.45 ± 0.96	< 0.001
	Rectal	29.00 ± 1.91	28.46 ± 2.55	0.015	28.61 ± 2.53	< 0.001

Continuous variables are expressed as mean \pm standard deviation and compared by Mann-Whitney U-test except for age, which is normally distributed and compared by Student's t-test. Categorical variables are expressed as number (%) and compared using the χ^2 test.

¹Myocardial infarction history is included in patients with coronary artery disease history. This is the old history and is not associated with the onset of aortic dissection, which may involve coronary arteries and may cause new myocardial ischemia/infarction.

²Cerebrovascular accident includes stroke history and transient ischemic attack history.

³Stanford type A (DeBakey I) is defined as ascending aortic arch involvement and distal beyond, Stanford type B (DeBakey II) as involving from the left subclavian artery or distal beyond, and the rest as none-type A-none-type B (NANB) Stanford type, which is dissection involved in the proximal aortic arch, but not ascending aorta. There were no DeBakey III patients.

unit transfusion of RBC during their in-hospital stay (**Figure 3A**). Plasma and platelet transfusions were used mostly intraoperative to avoid bleeding and decrease the thoracic drainage output. Platelet level dropped drastically after the operation, especially in the conventional group, which may be caused by blood loss and/or heparin-induced thrombocytopenia (**Table 2**). In addition, compared with the ABO group, more patients in the conventional group required a platelet transfusion (13.9 vs. 26.9%, respectively, p = 0.009). Platelet levels showed an obvious increase after postoperative day 3, and no further platelet transfusions were necessary (**Figure 3B**).

Respiratory System and Inflammation

After transfer to the ICU, patients frequently regained consciousness before the mechanical ventilation was withdrawn.

The incidence of lung infection was lower in the ABO group compared with the conventional group (2.3 vs. 8.5%, respectively, p = 0.028). The postoperative wake-up time was much shorter in the ABO group compared with the conventional group, at 15.2 \pm 23.6 h vs. 20.1 \pm 26.5 h, respectively (p < 0.001), which may be because the superior central nervous system was well-protected via the ABO technique to a certain extent. The mechanical ventilation support time was 34.1 ± 41.0 h and 48.9 \pm 87.8 h (p = 0.133). The ABO group had short mechanical ventilation support time, 8.5% vs. 21.5% (p = 0.003) in the ABO group compared with the conventional group, respectively. The leukocyte counts revealed both neutrophil and total leukocyte counts were higher in the conventional group during the initial postoperative period (Figure 4). The neutrophil and total leukocyte counts dropped to preoperative levels before discharge, suggesting a favorable recovery during the in-hospital stay.



FIGURE 2 | Renal function. **(A1)** The trajectory of serum creatinine (Scr). **(A2)** Scr grading in the column. **(B1)** The trajectory of blood urea nitrogen (BUN). **(B2)** BUN grading in the column. **(C1)** The trajectory of uric acid (UA). **(C2)** UA grading in the column. Data points are represented by mean with standard deviation bars. The green band represents the referred normal range of the examination. The *P*-value of the continuous variable is represented above the standard deviation bar, which is calculated by Student's t-test (normally distributed) or Mann-Whitney U test (non-normally distributed) with no multiple comparison correction to the *P*-value. The *P*-value of the categorical variable is represented in the graded column to represent for each grade, or above the grade to represent a total, which is calculated by χ^2 test. **P* < 0.05.



grading in the column. Data points are represented by mean with standard deviation bars. *P < 0.05.

TABLE 2 | The early outcomes.

Variables	Aortic balloon occlusion ($N = 130$)	Conventional before matching ($N = 230$)	Р	Conventional after matching ($N = 130$)	Р
30-day mortality	6 (4.62)	18 (7.83)	0.241	15 (10.77)	0.063
Wake-up time (h)	15.16 ± 23.56 8.12 (4.92–13.80)	20.07 ± 26.49 11.75 (7.80–19.02)	<0.001	23.52 ± 32.71 11.92 (7.85–22.32)	<0.001
Mechanical ventilation (h)	34.13 ± 40.97 18.67 (13.30–36.87)	46.74 ± 106.69 21.48 (13.47–46.97)	0.217	48.93 ± 87.83 21.70 (13.52–55.23)	0.133
Prolonged mechanical ventilation (>72 h)	11 (8.46)	42 (18.26)	0.012	28 (21.54)	0.003
CU stay (h)	119.90 ± 106.32 90.53 (59.33–132.75)	119.69 ± 123.36 86.38 (58.67–134.15)	0.380	131.14 ± 150.00 86.38 (44.32–136.58)	0.415
Postoperative in-hospital stay (d)	11.80 ± 5.35 11 (8–14)	12.42 ± 6.03 11 (9–14)	0.321	12.34 ± 6.70 10 (8–14)	0.900
Acute kidney injury	30 (23.08)	82 (35.65)	0.013	50 (38.46)	0.007
Continuous renal replacement therapy	10 (7.69)	23 (10.00)	0.466	21 (16.15)	0.037
Stroke	4 (3.08)	9 (3.91)	0.683	6 (4.62)	0.519
remporal paraplegia	3 (2.31)	10 (4.35)	0.319	7 (5.38)	0.197
Delirium	4 (3.08)	15 (6.25)	0.160	10 (7.69)	0.099
lepatic injury	16 (12.31)	64 (27.83)	0.001	39 (30.00)	<0.001
Acute pancreatitis	6 (4.62)	22 (9.57)	0.091	13 (10.00)	0.095
Severe lung infection	3 (2.31)	18 (7.83)	0.032	11 (8.46)	0.028
Re-exploration for bost-operative bleeding	7 (5.38)	9 (3.91)	0.515	8 (6.15)	0.790
_eft recurrent nerve injury	4 (3.08)	1 (0.008)	0.040	1 (0.004)	0.176
otal chest tube drainage o	of 0–3 postoperative day (r	nl)			
Operation day	429.15 ± 585.05	403.21 ± 264.47	0.760	432.72 ± 309.23	0.484
Postoperative day 1	321.47 ± 201.07	381.23 ± 213.73	0.001	375.35 ± 218.95	0.006
Postoperative day 2	211.34 ± 192.45	269.51 ± 179.42	< 0.001	259.13 ± 175.19	0.001
Postoperative day 3	176.03 ± 143.73	223.86 ± 148.50	< 0.001	213.29 ± 130.12	0.003
Prothrombine X (IU) usage	1144.26 ± 293.47 122 (93.85)	1303.51 ± 401.08 228 (99.13)	<0.001 (0.003)	1321.19 ± 381.82 119 (91.54)	<0.001 (0.475)
Novoseven (mg) usage	2.11 ± 0.56 83 (63.85)	$\begin{array}{c} 2.23 \pm 0.64 \\ 147 \ (63.91) \end{array}$	0.084 (0.990)	2.12 ± 0.66 78 (60.00)	0.863 (0.523)
ransfusion requirement (a	verage per patients and p	ercentage of usage)			
Red blood cell (u) total	4.98 ± 6.53 83 (63.85)	6.47 ± 8.51 174 (75.65)	0.042 (0.017)	7.28 ± 10.41 99 (76.15)	0.008 (0.030)
Operative	2.06 ± 3.15 55 (42.31)	3.02 ± 4.53 117 (50.87)	0.090 (0.118)	3.64 ± 5.19 74 (56.92)	0.009 (0.018)
Postoperative	2.92 ± 4.50 65 (50.00)	3.45 ± 6.18 132 (57.39)	0.351 (0.176)	4.17 ± 7.55 80 (61.54)	0.101 (0.061)
Plasma (ml) total	488.37 ± 573.32 82 (63.08)	614.78 ± 833.55 141 (61.30)	0.397 (0.739)	725.58 ± 992.81 86 (66.15)	0.120 (0.604)
Operative	302.33 ± 399.31 71 (54.62)	367.83 ± 432.13 124 (53.91)	0.292 (0.898)	400.00 ± 445.11 77 (59.23)	0.089 (0.452)
Postoperative	186.05 ± 354.60 42 (32.31)	246.96 ± 576.29 73 (31.74)	0.887 (0.912)	325.58 ± 716.36 47 (36.15)	0.337 (0.513)
Platelets (u) total	1.16 ± 0.99 102 (78.46)	1.40 ± 1.53 189 (82.17)	0.245 (0.390)	1.62 ± 1.84 112 (86.15)	0.049 (0.104)
Operative	0.86 ± 0.66 93 (71.54)	0.92 ± 0.90 172 (74.78)	0.675 (0.502)	0.95 ± 0.99 99 (76.15)	0.595 (0.397)
Postoperative	0.29 ± 0.84 18 (13.85)	0.48 ± 1.28 51 (22.17)	0.078 (0.054)	0.68 ± 1.62 35 (26.92)	0.015 (0.009)

Continuous variables are expressed as mean \pm standard deviation and compared by the Mann-Whitney U-test. Categorical variables are expressed as number (%) and compared using the χ^2 test.



FIGURE 4 | Leukocyte test. (A1) The trajectory of total leukocyte count. (A2) Total leukocyte count grading in the column. (B1) The trajectory of neutrophil count. (B2) Neutrophil count grading in the column. Data points are represented by mean with standard deviation bars. *P < 0.05.

Hepatic System Results

Hepatic complications were reflected by postoperative transaminase, and the ABO group had a lower incidence of hepatic injury (12.3 vs. 30.0%, p < 0.001) than the conventional group. The average level of ALT progressively increased in the ABO group during the in-hospital stay, and the conventional group rapidly increased in the first three postoperative days and fell to a similar level to that of the ABO group. Both groups had a sharp growth in average levels of AST during the ICU stay, and these gradually recovered to normal levels after patients were transferred back to the ward (**Figure 5**). The tendency of ALT and AST, therefore, played an important role in indicating hepatic injury.

DISCUSSION

In our institution, TAR with FET is the standard method to treat AD and other complexed aortic arch diseases (2); it is a safe and effective strategy (7) with promising long-term outcomes (3). Recently, the ABO technique was applied to TAR with FET. Its use consistently shortened the lower body CA time and raised the target nadir temperature, improving organ protection during the operation. Due to the complexity of postoperative complications, multi-system real-time surveillance is required during the ICU stay (8). This study investigated the effects of the ABO technique on the clinical outcomes, through continuous monitoring of patients' blood examination results during the in-hospital stay.

Renal injury was defined by Scr increase or urine output decrease. In our results, all oliguria and anuria received CRRT treatment, and AKI was graded by Scr level. Scr levels in both groups rose during the stay in the ICU but had recovered to preoperative levels before discharge. The postoperative Scr levels in the ABO group were consistently lower than that in the conventional group. The ABO technique may improve blood perfusion in the kidneys. Increasing the CA temperature alone cannot provide renal protective effects if CA time is not shortened (9).

Over the past few decades, transfusions in our hospital have greatly improved. Significant improvements have been achieved using the ABO technique, with a reduction in RBC, plasma, and platelet transfusion volumes, as well as reduced bleeding control times and thoracic drainage output. This benefit may be due to an improved postoperative coagulation function strategy, which may also be related to the use of the ABO technique. A previous study found that a decrease in patients' postoperative platelet counts was associated with the severity of AKI (10). A rebound in the number of platelets was also observed in the current study, as indicated by the persistent platelet activation and aggregation in the initial postoperative period (10). The postoperative platelet count may increase to such a high level that anti-platelet therapy could be actively proposed following a suitable evaluation. Moreover, the FET procedure was considered as a risk factor that may increase the incidence of spinal cord ischemia (11). Thus, anti-platelet therapy and dynamic assessment of limb movement should be considered in patients with high postoperative platelet counts to reduce the risk of thrombi.

The hepatic function was also significantly improved by the ABO technique; the AST was significantly higher in the conventional group and the ALT increased steadily during the in-hospital stay and exceeded the AST level before discharge. Previous studies highlight how AST is more sensitive than ALT in predicting postoperative hepatic injury (12–14). In our investigation, the AST level was high during the initial postoperative period, although it returned to normal levels following transfer out of the ICU. This demonstrates that AST was a more sensitive indicator to evaluate the hepatic injury suffered from the CPB procedure, while ALT was more strongly associated with drug-induced hepatic injury. Although ALT levels increased during the in-hospital stay in line with drug usage, most cases did not need specific hepatoprotective treatment (15).

The ABO technique significantly shortened the postoperative wake-up time, which may provide an improved protective effect on the central nervous system, although this hypothesis needs further investigation. In addition, the subsequent mechanical ventilation support time was shortened, and the pulmonary infection rate was also low.

This study has several limitations. First, this is a retrospective study and we only presented the data within a short period, mainly because the technique was only invented in August 2017, although this makes the standard of ICU care included in the study as uniform as possible. Second, as a historical comparison, the influence of increasing team experience may also create potential bias. Third, propensity score matching is wellperformed but could not adjust differences for every indicator analyzed in this study, and results of some comparisons may have been impacted. In addition, as for this new technique we introduced, it is not suitable for the following situations: where both femoral arteries are not suitable for cannulation; the DTA has formed a large aneurysm at the suture level of the trifurcated graft; or where Cronus stents have been implanted. There is still space for improvement of the new technique and we will continue our study in the future.

CONCLUSIONS

We systematically introduced a new ABO technique, based on the primary clinical outcomes, and this new method is not inferior to the traditional approach. Furthermore, some improved clinical outcomes were seen in the ABO group. Although there were no significant statistical differences between the two groups, in some respects, the clinical outcomes of the ABO group were improved compared with those of the conventional group. However, the sample size of the current study is small. We hope to enroll more patients to further investigate the value in the clinical application of this new technique.

The ABO technique may serve as an important operative method that improves the blood perfusion of organs and the recovery process during the in-hospital stay. However, the aortic balloon occlusion technique cannot be seen as a perfect technique that avoids all complications. We believe that continuous perfusion via the ABO technique is crucial in diminishing



(B2) AST grading in the column. Data points are represented by mean with a standard error of mean bars. *P < 0.05.

operative injury rates in high-risk patients. Therefore, using this new technique in TAR-FET may encourage cardiac surgeons to aim for improved clinical outcomes in this complex group of patients.

DATA AVAILABILITY STATEMENT

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by the Institutional Ethics Committee of Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences, and Peking Union Medical College (No: 2018-1069). Written informed consent for participation was not required for this study in accordance with the national legislation and the institutional requirements.

REFERENCES

- Liu ZG, Sun LZ, Chang Q, Zhu JM, Dong C, Yu CT, et al. Should the "elephant trunk" be skeletonized? Total arch replacement combined with stented elephant trunk implantation for Stanford type A aortic dissection. J Thorac Cardiovasc Surg. (2006) 131:107–13. doi: 10.1016/j.jtcvs.2005.09.015
- Sun L, Qi R, Zhu J, Liu Y, Zheng J. Total arch replacement combined with stented elephant trunk implantation: a new "standard" therapy for type a dissection involving repair of the aortic arch? *Circulation*. (2011) 123:971– 8. doi: 10.1161/CIRCULATIONAHA.110.015081
- Ma WG, Zhang W, Wang LF, Zheng J, Ziganshin BA, Charilaou P, et al. Type A aortic dissection with arch entry tear: surgical experience in 104 patients over a 12-year period. *J Thorac Cardiovasc Surg.* (2016) 151:1581– 92. doi: 10.1016/j.jtcvs.2015.11.056
- Sun X, Guo H, Liu Y, Li Y. The aortic balloon occlusion technique in total arch replacement with frozen elephant trunk. *Eur J Cardiothorac Surg.* (2019) 55:1219–21. doi: 10.1093/ejcts/ ezy369
- 5. Yan TD, Tian DH, LeMaire SA, Hughes GC, Chen EP, Misfeld M, et al. Standardizing clinical end points in aortic arch surgery a consensus statement from the international aortic arch surgery study group. *Circulation.* (2014) 129:1610–6. doi: 10.1161/CIRCULATIONAHA.113.0 06421
- Wang Y, Ji H. Comparison of two different red blood cell transfusion thresholds on short-term clinical outcomes of patients undergoing aortic surgery with deep hypothermic circulatory arrest. *J Cardiothorac Vasc Anesth.* (2016) 30:1163–6. doi: 10.1053/j.jvca.2016.03.128
- Parikh N, Trimarchi S, Gleason TG, Kamman AV, Di Eusanio M, Myrmel T, et al. Changes in operative strategy for patients enrolled in the international registry of acute aortic dissection interventional cohort program. *J Thorac Cardiovasc Surg.* (2017) 153:S74–9. doi: 10.1016/j.jtcvs.2016.12.029
- Hlaing M. Immediate ICU care for patients following aortic arch surgery. Semin Cardiothorac Vasc Anesth. (2016) 20:333– 42. doi: 10.1177/1089253216662149
- Fang Z, Wang G, Liu Q, Zhou H, Zhou S, Lei G, et al. Moderate and deep hypothermic circulatory arrest has a comparable effect on acute kidney injury after total arch replacement with frozen elephant trunk procedure in type A aortic dissection. *Interact Cardiovasc Thorac Surg.* (2019) 29:130–6. doi: 10.1093/icvts/ivz092
- 10. Tew S, Fontes ML, Greene NH, Kertai MD, Ofori-Amanfo G, Jaquiss RD, et al. Natural history of nonimmune-mediated thrombocytopenia and acute kidney

AUTHOR CONTRIBUTIONS

LW and XS: conception and design. ZC: administrative support. YL and SL: provision of study materials or patients. LW: collection and assembly of data. LW and JL: data analysis and interpretation. LW, ZC, YL, JL, HG, SL, and XS: article writing and final approval of article. All authors contributed to the article and approved the submitted version.

FUNDING

This study was supported by Beijing Municipal Science and Technology Commission, China, Major Special Project #Z181100001718197.

ACKNOWLEDGMENTS

The authors thank Miss Shuang Han, who is a MD and Ph.D. candidate from Shandong University Cheeloo College of Medicine, for her figure drawing.

injury in pediatric open-heart surgery. Paediatr Anaesth. (2017) 27:305-13. doi: 10.1111/pan.13063

- Hanif H, Dubois L, Ouzounian M, Peterson MD, El-Hamamsy I, Dagenais F, et al. Aortic arch reconstructive surgery with conventional techniques vs frozen elephant trunk: a systematic review and meta-analysis. *Can J Cardiol.* (2018) 34:262–73. doi: 10.1016/j.cjca.2017.12.020
- Scrascia G, Rotunno C, Simone S, Montemurno E, Amorese L, De Palo M, et al. Acute kidney injury in high-risk cardiac surgery patients: roles of inflammation and coagulation. J Cardiovasc Med. (2017) 18:359– 65. doi: 10.2459/JCM.0000000000343
- van Boxtel AG, Bramer S, Soliman Hamad MA, van Straten AH. Perioperative serum aspartate aminotransferase level as a predictor of survival after coronary artery bypass grafting. *Ann Thorac Surg.* (2012) 94:1492– 8. doi: 10.1016/j.athoracsur.2012.05.098
- Adachi K, Toyama H, Kaiho Y, Adachi O, Hudeta H, Yamauchi M. The impact of liver disorders on perioperative management of reoperative cardiac surgery: a retrospective study in adult congenital heart disease patients. J Anesth. (2017) 31:170–7. doi: 10.1007/s00540-017-2308-4
- Chin JH, Jo JY, Lee EH, Kim WJ, Choi DK, Sim JY, et al. Prognostic impacts of increases in amino transaminases following coronary artery bypass grafting on mortality. *J Cardiothorac Vasc Anesth.* (2018) 32:1236– 4. doi: 10.1053/j.jvca.2017.08.012

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 Wang, Cheng, Li, Li, Guo, Liang and Sun. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.